[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1986

Longitudinal Measurement of Plasma Homovanillic Acid Levels in Schizophrenic PatientsCorrelation With Psychosis and Response to Neuroleptic Treatment

Author Affiliations

From the Section on Clinical Studies, Clinical Neuroscience Branch, National Institute of Mental Health (Drs Pickar, Labarca, Doran, Wolkowitz, Roy, Breier, and Paul), and the National Institute on Alcohol Abuse and Alcoholism, Laboratory of Clinical Studies (Dr Linnoila), Bethesda, Md.

Arch Gen Psychiatry. 1986;43(7):669-676. doi:10.1001/archpsyc.1986.01800070059008
Abstract

• The plasma levels of homovanillic acid (HVA), a major circulating dopamine (DA) metabolite, were measured in schizophrenic patients during five weeks each of double-blind placebo-controlled neuroleptic treatment (N =16) and withdrawal (N =11). Both neuroleptic treatment and withdrawal were associated with time-dependent changes in the plasma levels of HVA; treatment was associated with decreases and withdrawal with increases. The levels of plasma HVA measured longitudinally during both conditions were highly correlated with psychosis ratings. Moreover, changes in individual mean weekly levels of plasma HVA were predictive of treatment response, including changes in both positive and negative symptoms of schizophrenia. These data are consistent with the suggestion that the mechanisms of action of antipsychotic drugs involve, in addition to short-term DA receptor blockade, a slowly developing decrease in presynaptic DA activity.

×